Guggenheim Reiterates Buy on Xenon Pharmaceuticals, Maintains $49 Price Target
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Yatin Suneja reiterated a Buy rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $49 price target.
June 15, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja reiterated a Buy rating on Xenon Pharmaceuticals and maintained a $49 price target.
The Guggenheim analyst's reiteration of a Buy rating and maintaining a $49 price target for Xenon Pharmaceuticals (XENE) indicates a positive outlook for the stock. This news is likely to have a positive impact on XENE's stock price in the short term as it shows confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100